Added to YB: 2025-05-09
Pitch date: 2025-05-08
MURA [neutral]
Mural Oncology plc
-21.84%
current return
Author Info
No bio for this author
Company Info
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer.
Market Cap
$36.1M
Pitch Price
$2.61
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.21
P/E
-0.30
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Special Situations Round-Up 19/25 - Mural Oncology plc
MURA (quick overview): Biotech spun off from $ALKS, trading at 0.40x P/NCAV. Halted Phase 3 & Phase 2 programs, only 2 pre-clinical candidates remain. Strategic review for sale/merger in progress, most staff terminated. Can't liquidate until Nov 2025 to maintain tax-free spin-off status. 30% held by funds including activist Soleus (6.3%).
Read full article (1 min)